Structural modeling and experimental validation define the MxA-Thogotovirus nucleoprotein interface that drives restriction and escape
L. América Chi, Megan E. LevyiD, Rechel GeigeriD, Harmit Singh MalikiD, Jagdish Suresh PateliD
Abstract
The human MxA (myxovirus resistance protein A) host restriction factor inhibits orthomyxoviruses, such as Thogotovirus (THOV) and influenza A virus (IAV), by binding to their nucleoproteins. Despite being discovered over six decades ago, how MxA interacts with viral targets remains unclear. Earlier studies using evolutionary analysis and mutagenesis showed that the MxA L4 loop, especially a hydrophobic aromatic amino acid at residue 561, is crucial for binding THOV nucleoprotein (NP) and restricting THOV. Here, we combined previous insights with structure prediction methods, molecular dynamics simulations, and experimental validation to define the human MxA L4 loop binding interface to THOV NP. We also evaluated the stability of MxA L4-NP binding through classical all-atom molecular dynamics simulations. Our model revealed MxA L4 binding to a surface-exposed site on THOV NP, including residues previously linked to viral escape from MxA restriction, even though this information was not used to guide our modeling efforts. This MxA-THOV NP interface is distinct from NPs RNA-binding or oligomerization surfaces. Our molecular dynamics simulations also agree with earlier data indicating that F561Y enhances MxA binding to THOV NP, whereas F561W reduces it and F561V ablates it entirely. Based on this model, we predicted specific variants in human MxA or THOV NP that could result in increased host restriction or viral escape. We tested these predictions using a viral minireplicon assay to validate our model. Our efforts will guide vital viral surveillance studies and the development of MxA-based antivirals. (240) Significance StatementThe interferon-stimulated MxA protein encodes a critical barrier to zoonotic spillover of orthomyxoviruses, restricting infection by binding viral nucleoprotein (NP). Despite being among the best-studied interferon-stimulated genes (ISGs), the specific host-viral interaction surface involved in binding or restriction is poorly understood. We address this hurdle using structural modeling and molecular dynamics simulations to generate a model of the biochemical interactions between MxA and Thogotovirus NP. Our model is consistent with previous work identifying mutations that strengthen or weaken the binding interaction. We validate this model using in vitro analysis of predicted mutations at the host-virus interface. Our model provides a framework for additional mutational studies, surveillance of viruses poised for zoonosis, and rational antiviral design. (115)
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The antiviral mechanism of MxA revealed by a molecular docking-based structural model of the complex of MxA and influenza A virus NP/RNPs
Yeping Sun·bioRxiv·Nov 15, 2017
- Combinatorial mutagenesis of rapidly-evolving residues yields super-restrictor antiviral proteins
R. Colon-Thillet, E. Hsieh, … H. S. Malik·bioRxiv·Aug 12, 2019
- Heterozygous and generalist MxA super-restrictors overcome breadth-specificity tradeoffs in antiviral restriction
Rechel Geiger, Damini Khera, … Harmit Singh Malik·Science AdvancesPeer-reviewed·May 2, 2025
- Targeted Engineering of Human MxA Yields a Broad-Spectrum Super-Restrictor of Human-Adapted Influenza Viruses
Megan E. Levy, Rechel Geiger, … Harmit Singh Malik·bioRxiv·Oct 23, 2026
- Deep mutational scanning identifies sites in influenza nucleoprotein that affect viral inhibition by MxA
Orr Ashenberg, Jai Padmakumar, … Jesse Bloom·bioRxiv·Aug 28, 2016
- The antiviral GTPase MxB is packaged into virions and binds via its N-terminal domain to alphaherpesvirus capsids
Sebastian Weigang, Manutea Christophe Serrero, … Beate Sodeik·PLoS PathogensPeer-reviewed·Jul 16, 2026